FDA Approved: AQVESME — Supplemental Application (Agios Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for AQVESME (mitapivat) submitted by Agios Pharmaceuticals, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyruvate Kinase Deficiency

Drugs mentioned

• AQVESME (mitapivat)

Snippet

SUPPL AP for AQVESME (MITAPIVAT)